The proportion of the population with immunocompromising conditions, who are at increased risk for complications from infectious diseases, continues to grow. Concurrently, outbreaks due to known and e...

The proportion of the population with immunocompromising conditions, who are at increased risk for complications from infectious diseases, continues to grow. Concurrently, outbreaks due to known and e...

In an in-depth immunological analysis of alternate influenza vaccination strategies in high-risk patients receiving therapy for hematological malignancy, p

Cytomegalovirus (CMV) reactivation occurred in 27% of CMV-seropositive chimeric antigen receptor–modified T-cell immunotherapy (CARTx) recipients within 12

The proportion of immunocompromised individuals in the United States has grown rapidly and currently accounts for 6.6% of the US population [1]. Individual

People affected by haematological malignancies are at high risk of morbidity and mortality caused by vaccine-preventable infections. However, vaccinat…

In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

Despite widespread adoption of “high-dose” glucocorticoid definitions across international immunisation guidelines (i.e., prednisone-equivalent dosing >20 mg/day, or >2 mg/kg/day in children), the rationale remains unclear. Literature searches were performed through academic databases for this narrative review to identify relevant evidence regarding glucocorticoid dosing on vaccine responses and safety.